Search Results - "Erkişi, Melek"

Refine Results
  1. 1
  2. 2

    Discordance Between HER-2/NEU Expression Assessed Using Immunohistochemistry (IHC) And Fluorescence In Situ Hybridization (FISH): Is It Important To Detect? by Duman,Berna Bozkurt, Sahin,Berksoy, Kara,İsmail Oğuz, Erkişi,Melek, Kıdık,Adem

    Published in Cukurova Medical Journal (01-01-2014)
    “…Purpose: Assessment of HER-2 has become of great importance following the advent of HER-2 antibody treatment. Use of trastuzumab therapy depends on the…”
    Get full text
    Journal Article
  3. 3

    Environmental Malignant Mesothelioma in Southern Anatolia: A Study of Fifty Cases by Zeren, E. Handan, Gümürdülü, Derya, Roggli, Victor L., Tuncer, Ilhan, Zorludemir, Suzan, Erkişi, Melek

    Published in Environmental health perspectives (01-11-2000)
    “…Malignant mesothelioma is a highly aggressive tumor of the serous membranes, which in humans results from exposure to asbestos and asbestiform fibers. Although…”
    Get full text
    Journal Article
  4. 4

    Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study by Gunaldi, Meral, Duman, Berna Bozkurt, Afsar, Cigdem Usul, Paydas, Semra, Erkisi, Melek, Kara, I Oguz, Sahin, Berksoy

    Published in Journal of oncology pharmacy practice (01-04-2016)
    “…Background Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with…”
    Get full text
    Journal Article
  5. 5

    Retrospective analysis of 498 primary soft tissue sarcomas in a single Turkish centre by Duman, Berna Bozkurt, Gunaldi, Meral, Ercolak, Vehbi, Afsar, Cigdem Usul, Sahin, Berksoy, Erkisi, I Melek Koksal, Kara, Oguz, Paydas, Semra, Gönlüsen, Gülfiliz, Sertdemir, Yaşar

    “…Soft tissue sarcomas (STS) must be managed with a team involving pathologists, radiologists, surgeons, radiation therapists and medical oncologists. Treatment…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Primary therapeutic decision-making in inoperable non-small cell lung cancer by Erkurt, E, Tunali, C, Erkişi, M

    “…To test the accuracy of our treatment decisions for patients with inoperable non-small cell lung cancer (NSCLC) using a prototype decision-support system (DSS)…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment by Günaldı, Meral, Erkisi, Melek, Afşar, Ciğdem Usul, Erçolak, Vehbi, Paydas, Semra, Kara, I Oguz, Sahin, Berksoy, Gulec, Umran Kucukgoz, Secilmis, Ata

    Published in Pharmacology (01-01-2014)
    “…Several previous studies have examined the effect of CYP2D6 gene polymorphism on the efficacy and metabolism of tamoxifen (Tamoxifen Teva, Nolvadex) in the…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Evaluation of Ki-67/PCNA immunostaining in breast carcinoma and cytologic grading of fine needle aspirates of breast carcinoma: Correlation with histologic grade by ERDOĞAN, Şeyda, ERSÖZ, Canan, ERKİŞİ, Melek, DEMİRCAN, Orhan, ERGİN, Melek

    Published in Annals of medical sciences (2002)
    “…Background: The reliability of breast cancer grading system in fine needle aspirates and correlation of histologic grade with immunohistologic application of…”
    Get full text
    Journal Article
  14. 14

    Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients by Duman, Berna Bozkurt, Afşar, Çiğdem Usul, Günaldi, Meral, Sahin, Berksoy, Kara, I Oguz, Erkisi, Melek, Erçolak, Vehbi

    “…Neoadjuvant systemic chemotherapy is the accepted approach for women with locally advanced breast cancer. Anthracycline- and taxane-based regimens have been…”
    Get full text
    Journal Article
  15. 15

    The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect? by Berna Bozkurt Duman, Berksoy Sahin, Oguz Ismail Kara, Melek Erkisi, Adem Kidik, Melek Ergin, Emine Kilic Bagir

    “…Purpose: Assessment of HER-2 has become of great importance following the advent of HER-2 antibody treatment. Use of trastuzumab therapy depends on the…”
    Get full text
    Journal Article
  16. 16
  17. 17

    HER-2/NEU Ekspresyonun Saptanmasinda İmmunohistokimyasal ve Fish Yöntemi Arasında Diskordansin Belirlenmesi Önemli midir? by Berna Bozkurt DUMAN, Berksoy ŞAHİN, Oğuz İsmail KARA, Melek ERKİŞİ, Adem KIDIK, Melek ERGİN, Emine Kılıç BAĞIR

    Published in Cukurova Medical Journal (01-07-2014)
    “…Amaç: HER-2"nin değerlendirilmesi, HER-2 antikor tedavisinin takibinde büyük öneme sahiptir. Transtuzumab tedavisinde HER-2"nin değerlendirilmesi protein aşırı…”
    Get full text
    Journal Article
  18. 18

    A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer by Erkisi, Melek, Doran, Figen, Burgut, Refik, Kocabas, Ali

    Published in Lung cancer (Amsterdam, Netherlands) (01-06-1995)
    “…Seventy-four newly diagnosed patients with histologically proven Stage III-B and IV non-small cell lung cancer were randomized to receive either cisplatin: 20…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Retrospective Analysis of Neoadjuvant Chemotherapy for Breast Cancer in Turkish Patients by Duman, Berna Bozkurt, Afsar, Cigdem Usul, Gunaldi, Meral, Sahin, Berksoy, Kara, I. Oguz, Erkisi, Melek, Ercolak, Vehbi

    “…Background: Neoadjuvant systemic chemotherapy is the accepted approach for women with locally advanced breast cancer. Anthracycline- and taxane-based regimens…”
    Get full text
    Journal Article